Hematopoietic and lymphoid tissue tumors in patients with innate immune adhesion function of red blood cells and on NK cell killing activity of.docVIP

 PAGE \* MERGEFORMAT 19 Hematopoietic and lymphoid tissue tumors in patients with innate immune adhesion function of red blood cells and on NK cell killing activity of Author: Nai-Hong, Feng Mei, Luk Yu Jin, Zhu Lei, Liu Jie, Gao Hong-peng, Li Weimin, Qiao Zhenhua [Abstract] This study investigated the hematopoietic and lymphoid tissue tumors in patients with red blood cells and red blood cell innate immune adhesion function of the NK cell killing activity. Sodium citrate anticoagulant in peripheral blood, detection of plasma red blood cells under the conditions of its own immune adhesion of K562 cells and calculate the adhesion rate. Determination of red blood cells with the MTT normal NK cell killing activity of K562 cells and red blood cells with non-Canadian when the comparison. The results showed: red blood cells of K562 cells to form a amp;quot;Roseamp;quot;-like combination. Normal human red blood cell immune adherence of K562 binding rate (15.3 ± 6.4)%, hematopoietic and lymphoid tissue tumors in patients with red blood cell immune adherence of K562 binding rate (7.6 ± 7.0)%, compared with normal subjects decreased significantly ( t = 3.61, p amp;lt;0.001). Without red blood cells under the conditions of normal human peripheral blood NK cell killing activity of K562 cells was 67% -71%. Normal human red blood cells significantly increased NK cell killing activity of K562 cells, killing rate (14.7 ± 5.2)%, hematopoietic and lymphoid tissue tumors in patients with red blood cells to reduce the NK cell killing activity of K562 cells, killing rate (4.3 ± 7.6)%, both compared There was significant difference (t = 6.73, p amp;lt;0.0001). Conclusion: The hematopoietic and lymphoid tissue tumors in patients with red blood cell adhesion of K562 cells, the immune reduced ability to normal human red blood cells significantly increased NK cell killing activity of K562 cells, while the hematopoietic and lymphoid tissue tumors in patients with red blood cells